Overview
Treace Medical Q2 2025 revenue rises 7%, beating analyst expectations, per LSEG data
Net loss improved by 18% to $17.4 mln, adjusted EBITDA loss reduced by 58%
Expanded bunion technology portfolio with new systems and increased patent holdings
Outlook
Treace reaffirms 2025 revenue guidance of $224 mln to $230 mln
Company expects breakeven Adjusted EBITDA for full-year 2025
Treace projects 50% reduction in cash usage for 2025
Result Drivers
TECHNOLOGY EXPANSION - Release of Nanoplasty, Percuplasty, and SpeedMTP systems contributed to revenue growth
OPERATING EFFICIENCIES - Reduction in operating expenses helped improve net loss figures
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $47.39 mln | $47.10 mln (6 Analysts) |
Q2 EPS | -$0.28 | ||
Q2 Gross Margin | 79.7% | ||
Q2 Gross Profit | $37.75 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Treace Medical Concepts Inc is $9.00, about 39.2% above its August 6 closing price of $5.47
Press Release: ID:nGNXbhyGfy
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。